Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Vicore Pharma Holding AB ( (SE:VICO) ) is now available.
Vicore Pharma Holding AB has called its Annual General Meeting for 6 May 2026 in Stockholm, giving shareholders the option to attend in person or vote in advance by post, subject to standard Euroclear Sweden registration and proxy requirements. The agenda includes approval of financial statements, discharge of the board and CEO, elections to the board and auditor roles, and adoption of remuneration and long-term equity-based incentive programs for directors and co-workers.
Shareholders will also vote on authorizing the board to issue new shares, warrants and convertibles, a move that would give Vicore Pharma additional flexibility to raise capital or structure incentive schemes as it advances its strategy. The proposed equity-based programs and capital-issuance mandate signal a continued emphasis on aligning management and board incentives with shareholder interests while preserving financial optionality in a capital-intensive biotech environment.
The most recent analyst rating on (SE:VICO) stock is a Hold with a SEK10.50 price target. To see the full list of analyst forecasts on Vicore Pharma Holding AB stock, see the SE:VICO Stock Forecast page.
More about Vicore Pharma Holding AB
Vicore Pharma Holding AB is a Sweden-based biopharmaceutical company focused on developing therapies in respiratory and rare diseases. The company operates in highly regulated life sciences markets, where shareholder governance and capital-raising flexibility are important for funding long-term research and development programs.
Average Trading Volume: 667,804
Technical Sentiment Signal: Sell
Current Market Cap: SEK2.77B
For detailed information about VICO stock, go to TipRanks’ Stock Analysis page.